Kirilys is a multi-asset, clinical-stage precision oncology company focused on improving the lives of patients with cancer through the development and improvement of therapeutic treatments. The company’s pipeline includes KRLS-004, an anti-5T4 antibody-drug conjugate, and KRLS-017, a reversible small molecule inhibitor of Cyclin Dependent Kinase 7 (CDK7).

Sign up for our newsletter

© All rights reserved Tarsadia